INTRODUCTION Plasma biomarkers are altered years prior to Alzheimer's disease (AD)
clinical onset. METHODS We measured longitudinal changes in plasma amyloid‐beta (Aβ) …

INTRODUCTION Understanding longitudinal plasma biomarker trajectories relative to brain
amyloid changes can help devise Alzheimer's progression assessment strategies …

Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early
changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels …

INTRODUCTION The timing of plasma biomarker changes is not well understood. The goal
of this study was to evaluate the temporal co‐evolution of plasma and positron emission …

Background Failures in drug trials strengthen the necessity to further determine the
neuropathological events during the development of Alzheimer's disease (AD). We sought to …

Introduction Plasma amyloid beta (Aβ) 1‐42/Aβ1‐40 ratio, phosphorylated‐tau181 (p‐
tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are putative blood …

Introduction Plasma biomarkers will likely revolutionize the diagnostic work‐up of
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …

Objective The objective of this study was to evaluate novel plasma p‐tau231 and p‐tau181,
as well as Aβ40 and Aβ42 assays as indicators of tau and Aβ pathologies measured with …

Plasma amyloid-β (Aβ) 42, phosphorylated tau (p-tau) 181, and neurofilament light chain
(NfL) are promising biomarkers of Alzheimer's disease (AD). However, whether these …

Background Previous studies reported the value of blood-based biomarkers in predicting
Alzheimer disease (AD) progression among individuals with different disease stages …